A group of researchers have created four novel laboratory-developed tests that can distinguish between and subclassify atopic dermatitis and psoriasis molecular markers. Image: Adobe Stock.

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

including lipids, metabolites, and peptides; clinical markers ... to assist with PsA diagnosis (iPROLEPSIS), to distinguish subtypes of atopic dermatitis and psoriasis using biomarkers (BIOMAP ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.